Glaxo touts effectiveness of pediatric vaccine candidate

GlaxoSmithKline is touting new, late-stage data that demonstrates how its experimental pediatric vaccine Synflorix effectively protects children from pneumococcal disease. Glaxo filed Synflorix for review by the EMEA at the beginning of the year. The new data illustrates its protection against 10 strains of streptococcus pneumoniae, which includes bacteria that causes meningitis, pneumonia and ear infections. If Glaxo prevails in its quest for regulatory approval, Synflorix will go up against Wyeth's Prevnar, which targets seven of the 10 strains.

"The data presented today are extremely encouraging and represent a major step forward to a pneumococcal conjugate vaccine formulation, specifically designed to address the global epidemiology of pneumococcal disease in both developed and developing countries," says Jean Stéphenne, president of GlaxoSmithKline Biologicals

- check out GSK's release
- read the Dow Jones report

Suggested Articles

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.

AZ is among the companies leading the COVID-19 vaccine race, and after agreeing first to supply the U.K., it's now in talks for delivery worldwide.